ROCHESTER, N.Y., May 12, 2025 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI) (“Vuzix” or the “Company”), a leading supplier of smart glasses, waveguides, and Augmented Reality (AR) technologies, today reported its first quarter results for the three months ended March 31, 2025.

“2025 has thus far been marked by important developments for Vuzix that span commercial and technology relationships, expansion of customer deployments, and enhancements enabling product execution,” said Paul Travers, President and CEO of Vuzix. “Vuzix is entering a phase of increasing commercial momentum, as our long-standing business model vision and investments are translating into design wins and tangible near-term commercial traction. At the same time, the broader tech industry is amplifying its focus on AI-powered smart glasses, signaling that the ultimate race to bring these products to scale is getting closer, if not already underway, as evidenced by increasing inbound activity.”

“And while the adoption of smart glasses in the entire market has been slower than anticipated by all market participants, Vuzix’ outlook remains very positive.  Our Q1 enterprise sales improved sequentially (Q1/25 vs Q4/24), driven by both new deployments and growing follow-on orders, and as we have previously shared, we have several strategic programs moving steadily toward large-scale rollout,” continued Mr. Travers. “With a growing base of ODM/OEM opportunities, new strategic partnerships, and rising interest for AI-enhanced wearable solutions, we believe the market is gaining momentum and Vuzix is well-positioned to capitalize as AI and AR technologies converge and reshape the way we work, communicate, and interact with digital information.”

The following table compares condensed elements of the Company’s unaudited summarized Consolidated Statements of Operations data for the three months ended March 31, 2025 and 2024, respectively:

First Quarter 2025 Financial Results

For the three months ended March 31, 2025, total revenues decreased by 21% to $1.6 million versus $2.0 million for the comparable period in 2024. The decrease in total revenues was due to lower product sales and specifically reduced unit sales of M400 smart glasses. Engineering services revenues were $0.3 million for the three months ended March 31, 2025 as compared to $0.2 million in the prior year’s quarter.

There was an overall gross loss of $0.3 million for the three months ended March 31, 2025 as compared to a gross loss of $0.1 million for the same period in 2024. The increased gross loss was due to the planned reductions of further product manufacturing builds of our existing smart glasses models as compared to 2024, that resulted in the expensing of the Company’s relatively fixed manufacturing overhead costs that were not counter-balanced by requisite revenue levels.

Research and Development expense was $2.6 million for the three months ended March 31, 2025, versus $2.7 million for the comparable 2024 period, a decrease of approximately 5%. This decrease was primarily due to reduced salary and benefits expenses, partially offset by increased external development costs on new products.

Selling and Marketing expense was $1.5 million for the three months ended March 31, 2025, versus $2.2 million for the comparable 2024 period, a decrease of approximately 31%. This decrease was primarily due to reduced salary and benefits expenses and lower advertising and tradeshow expenses.

General and Administrative expense for the three months ended March 31, 2025 was $4.0 million versus $4.1 million for the comparable 2024 period, a decrease of approximately 3%. This decrease was largely due to reduced overall compensation expenses.

The net loss decreased for the three months ended March 31, 2025 to $8.6 million, or $0.11 cents per share versus a net loss of $10.0 million, or $0.16 for the comparable period in 2024.

The cash net flows used in operating activities was $3.5M for the first quarter of 2025 versus $8.8M for the comparable 2024 period.

Management Outlook

“We ended March 2025 with working capital of $19.5 million and are confident that we have the capital resources to execute upon our current operating plan,” said Mr. Travers. “Our focus over the remainder of 2025 is to continue to secure design wins into new ODM/OEM products, for both consumer and enterprise applications. These should ideally develop into long-term recurring revenues where Vuzix will supply optical waveguides and display engines or create co-branded AI smart glasses products. In the defense space, we aim to grow our business with existing and new prime defense contractors, leading to new custom design-ins and an acceleration of scaled production orders.”

“We are also experiencing growing enterprise customer successes, supported by substantial customer use data sets demonstrating productivity improvements, utilizing applications from leading enterprise ISVs as well as Vuzix subsidiary, Moviynt®, that significantly surpass targeted customer benchmarks. We remain confident that anticipated follow-on orders for smart glasses this year have the potential to reduce our existing smart glasses inventory and convert those finished goods into cash, facilitating a smooth introduction of our next-generation, purpose-built products, the development of which are well underway.  Lastly, we remain very pleased with our burgeoning commercial relationships with Quanta and other key ODMs/OEMs and their forward commitments to us with both capital as well as commercial collaborations,” concluded Mr. Travers. 

Conference Call Information                                                                                                                       

Date: Monday, May 12, 2025
Time: 4:30 p.m. Eastern Time (ET)
Dial-in Number for U.S. & Canadian Callers: 877-709-8150
Dial-in Number for International Callers (Outside of the U.S. & Canada): 201-689-8354

A live and archived webcast of the conference call will be available on the investor relations page of the Company’s website at: https://ir.vuzix.com/ or directly at https://event.choruscall.com/mediaframe/webcast.html?webcastid=NAHi2gQc

Participating on the call will be Vuzix’ Chief Executive Officer and President Paul Travers and Chief Financial Officer Grant Russell, who together will discuss operational and financial highlights for the quarter ended March 31, 2025.

To join the live conference call, please dial into the above referenced telephone numbers five to ten minutes prior to the scheduled conference call time.

A telephonic replay will be available for 30 days, starting on May 12, 2025, at approximately 5:30 p.m. (ET). To access this replay, please dial 877-660-6853 within the U.S. or Canada, or 201-612-7415 for international callers. The conference replay ID# is 13753516.

About Vuzix Corporation

Vuzix is a leading designer, manufacturer and marketer of AI-powered Smart Glasses, Waveguides and Augmented Reality (AR) technologies, components and products for the enterprise, medical, defense and consumer markets. The Company’s products include head-mounted smart personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality, as well OEM waveguide optical components and display engines. Vuzix holds more than 425 patents and patents pending and numerous IP licenses in the fields of optics, head-mounted displays, and the augmented reality wearables field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2024 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in: Rochester, NY; and Kyoto and Okayama, Japan.  For more information, visit the Vuzix website, X and Facebook pages.

Forward-Looking Statements Disclaimer

Certain statements contained in this news release are “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward-looking statements contained in this release relate to, among other things, the timing of new product releases, smart glass pilot to roll-out conversion rates, opportunities related to market disruptions regarding smart glasses demand, R&D project successes, smart glasses pilot to roll-out conversion rates, existing and new engineering services and conversion to volume production OEM programs, future revenue and operating results, and the Company’s leadership in the Smart Glasses and AR display industry. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the Company’s Annual Reports and other filings with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Investor Relations Contact

Ed McGregor, Director of Investor Relations
Vuzix Corporation
ed_mcgregor@vuzix.com
Tel: (585) 359-5985

Vuzix Corporation, 25 Hendrix Road, West Henrietta, NY 14586 USA,
Investor Information – IR@vuzix.com www.vuzix.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vuzix-reports-first-quarter-2025-results-302452820.html

SOURCE Vuzix Corporation

MENLO PARK, Calif., May 12, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will integrate ordering of GRAIL’s Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core, a service designed to help streamline laboratory order transmission and care coordination for healthcare facilities. The integration will be provided through athenaOne, athenahealth’s leading cloud-based electronic health record (EHR) solution.

Integration with athenaCoordinator Core will allow over 160,000 U.S. clinicians on the athenahealth network to opt in to more seamlessly order Galleri directly in the EHR, reducing additional ordering steps. After the clinician’s order is placed, the patient can take the Galleri test kit to a blood draw appointment. The Galleri test results will be made available automatically in the patient chart, reducing manual entry and administrative burden for the clinician’s practice.

“Cancer remains a public health crisis. There is a clear need to transform the way we screen for cancer while still asymptomatic, when it can be more easily treated,” said Josh Ofman, MD, MSHS, president at GRAIL. “Integrating with athenaCoordinator Core will help simplify the Galleri test ordering process as part of routine exams and help increase patient access to multi-cancer early detection to screen for some of the deadliest cancers before they become symptomatic.”

Cancers growing in the body shed DNA into the bloodstream. These DNA fragments act like a unique “fingerprint” of cancer. With a single blood draw, the Galleri test screens for the “fingerprint” of many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests today. It can also provide doctors with information on the cancer’s origin to help predict the tissue type or organ associated with the cancer signal. The Galleri test is prescription only, recommended for adults with an elevated risk for cancer, such as those age 50 or older, and is to be used in addition to recommended cancer screenings.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

About Galleri®
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique “fingerprint” of cancer, to help screen for some of the deadliest cancers that don’t have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others.* The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.

For more information, visit galleri.com.

Sensitivity in study participants with –
Pancreas cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV). Esophagus cancer 85.0% overall (12.5% stage I, 64.7% stage II, 94.7% stage III, 100% stage IV). Ovary cancer: 83.1% overall (50.0% stage I, 80.0% stage II, 87.1% stage III, 94.7% stage IV). Liver/bile duct cancer: 93.5% overall (100% stage I, 70.0% stage II, 100% stage III, 100% stage IV).

Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

Forward Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” “would,” or “will,” the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include expectations about or projections ease of ordering Galleri, potential increases in patient access, clinical impact, technology, clinical and real world studies, regulatory compliance, potential market opportunity, anticipated growth strategies, and other topics.

These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the section entitled “Risk Factors” in our Annual Report on Form 10-Q for the period ended March 31, 2025 and our Form 10-K for the period ended December 31, 2024 (the “Form 10-K”). Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.

Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-and-athenahealth-team-up-to-offer-healthcare-providers-streamlined-ordering-of-grails-galleri-multi-cancer-early-detection-mced-test-302452612.html

SOURCE GRAIL, Inc.

Total revenue increased 17% to $134.1 million

Net income of $8.0 million at a 6% margin; adjusted EBITDA of $41.5 million at a 31% margin 

Raises midpoint of full-year revenue and adjusted EBITDA outlook

NEW YORK, May 12, 2025 /PRNewswire/ — Integral Ad Science (Nasdaq: IAS), a leading global media measurement and optimization platform, today announced financial results for the first quarter ended March 31, 2025.

“We exceeded our expectations for the first quarter with 17% revenue growth highlighted by a 24% increase in optimization revenue and a 33% increase in publisher revenue,” said Lisa Utzschneider, CEO of IAS. “IAS is an AI-first company. We empower global marketers to optimize their digital investments and realize their target outcomes with our advanced technology. We are executing on our strategy as we prioritize performance, product innovation, and global reach. We are raising the midpoint of our full-year financial outlook to reflect our strong first quarter performance.”

First Quarter 2025 Financial Highlights

Total revenue was $134.1 million, a 17% increase compared to $114.5 million in the prior-year period.Optimization revenue was $64.8 million, a 24% increase compared to $52.5 million in the prior-year period.Measurement revenue was $48.4 million, a 4% increase compared to $46.3 million in the prior-year period.Publisher revenue was $20.9 million, a 33% increase compared to $15.8 million in the prior-year period.International revenue, excluding the Americas, was $42.7 million, an 18% increase compared to $36.0 million in the prior-year period, or 32% of total revenue for the first quarter of 2025.Gross profit was $103.9 million, an 18% increase compared to $88.4 million in the prior-year period. Gross profit margin was 78% for the first quarter of 2025.Net income was $8.0 million, or $0.05 per basic and diluted share, compared to a net loss of $1.3 million, or $0.01 per basic and diluted share, in the prior-year-period. Net income margin was 6% for the first quarter of 2025.Adjusted EBITDA* was $41.5 million compared to $33.1 million in the prior-year period. Adjusted EBITDA* margin was 31% for the first quarter of 2025.Cash and cash equivalents were $59.1 million at March 31, 2025.

Recent Business Highlights 

TikTok Social Optimization Expansion – In April, IAS announced an expansion of Social Optimization for TikTok to include pre-bid Video Level Exclusion Lists. Paired with TikTok’s Inventory Filter, advertisers applying pre-bid Video Level Exclusion Lists benefit from pre-bid granular exclusions, powered by IAS’s multimedia technology and based on brand-specific needs.Reddit Total Media Quality (TMQ) Expansion – In April, IAS announced the expansion of its partnership with Reddit to include Viewability and Invalid Traffic Measurement, as part of IAS’s TMQ for Reddit. This expansion builds on IAS’s earlier integration with Reddit to provide brand safety and suitability measurement.Google Search Partner Network (SPN) Expansion – In May, IAS announced the launch of IAS’s Pre-Screen brand safety solution for SPN. With this launch, IAS will provide advertisers with additional control over their investments before their ads are shown across the network.Spotify Podcast Tools – In May, IAS announced with Spotify the launch of new brand safety and suitability targeting and measurement tools for podcast advertisers for the Spotify Audience Network.Nextdoor Pre-Bid Partnership – In May, IAS announced a strategic first-to-market partnership with Nextdoor. IAS will now power Nextdoor’s first-party brand safety tool as a provider of pre-bid brand safety and suitability optimization on the platform.Roblox Measurement Partnership Update – In April, Roblox announced that IAS will offer coverage across media quality and performance solutions, including fraud, brand safety and suitability, and viewability.

Financial Outlook

IAS is providing the following financial outlook for the second quarter of 2025 and raising the midpoint of its full year 2025 revenue and adjusted EBITDA outlook:

Second Quarter Ending June 30, 2025:

Total revenue of $142 million to $144 millionAdjusted EBITDA* of $45 million to $47 million

Year Ending December 31, 2025:

Total revenue of $590 million to $600 millionAdjusted EBITDA* of $204 million to $210 million

Financial outlook is based on information as of today, May 12, 2025, and may be impacted by factors outside IAS’s control. See “Forward Looking Statements.”

* See “Supplemental Disclosure Regarding Non-GAAP Financial Information” section herein for an explanation of these measures. IAS is unable to provide a reconciliation for forward-looking guidance of adjusted EBITDA and corresponding margin to net income (loss) and corresponding margin, the most closely comparable GAAP measures without unreasonable effort, because certain material reconciling items, such as depreciation and amortization, interest expense, income tax expense (benefit) and acquisition, restructuring and integration expenses, cannot be estimated due to factors outside of IAS’s control and could have a material impact on the reported results. However, IAS estimates stock-based compensation expense for the second quarter of 2025 in the range of $19 million to $21 million and for the full year 2025 in the range of $72.5 million to $75.5 million.

Supplemental Disclosure Regarding Non-GAAP Financial Information
We use supplemental measures of our performance, which are derived from our consolidated financial information, but which are not presented in our consolidated financial statements prepared in accordance with GAAP. Adjusted EBITDA is the primary financial performance measure used by management to evaluate our business and monitor ongoing results of operations. Adjusted EBITDA is defined as net income (loss) before depreciation and amortization, stock-based compensation, interest expense, net, provision (benefit) from income taxes, acquisition, restructuring and integration costs and foreign exchange gains and losses, and other one-time, non-recurring costs. Adjusted EBITDA margin represents the adjusted EBITDA for the applicable period divided by the revenue for that period presented in accordance with GAAP.

We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our shareholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period-to-period comparisons. Although we believe these measures are useful to investors and analysts for the same reasons they are useful to management, these measures are not a substitute for, or superior to, U.S. GAAP financial measures or disclosures and should be read only in conjunction with financial information presented on a U.S. GAAP basis. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Reconciliation of historical Adjusted EBITDA and corresponding margin to their most directly comparable GAAP financial measures, net income (loss) and corresponding margin are presented below. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future fiscal periods, we may exclude such items and may incur income and expenses similar to these excluded items.

Conference Call and Webcast Information
IAS will host a conference call and live webcast to discuss its first quarter 2025 financial results today at 5:00 p.m. ET. To access the live webcast and conference call dial-in, please register under the “News & Events” section of IAS’s investor relations website. A replay will be available on IAS’s investor relations website following the live call: https://investors.integralads.com.

About Integral Ad Science
Integral Ad Science (IAS) is a leading global media measurement and optimization platform that delivers the industry’s most actionable data to drive superior results for the world’s largest advertisers, publishers, and media platforms. IAS’s software provides comprehensive and enriched data that ensures ads are seen by real people in safe and suitable environments, while improving return on ad spend for advertisers and yield for publishers. Our mission is to be the global benchmark for trust, safety, and transparency in digital media quality. For more information, visit integralads.com.

Forward-Looking Statements
This earnings press release contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance, including guidance, and business, including pipeline and industry trends. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected costs, expenditures, cash flows, growth rates and financial results, including forecasted revenue and adjusted EBITDA, or our plans and objectives for future operations and products, growth initiatives or strategies, expected features and functionality of our products, and expectations regarding technology, including the use of artificial intelligence, are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including: (i) factors that affect the amount of advertising spending, such as economic downturns and marketability, uncertainty surrounding the stability of economic conditions due to new and proposed tariffs and uncertainty in the global trade environment, instability in geopolitical or market conditions generally, and any changes in tax treatment of advertising expense; (ii) our failure to innovate or make the right investment decisions; (iii) our ability to provide digital or cross-platform analytics; (iv) our ability to sustain our profitability and revenue growth rate, particularly if our revenue continues to decline; (v) issues in the development and use of artificial intelligence and machine learning; (vi) our failure to maintain or achieve industry accreditation standards; (vii) our dependence on integrations with advertising platforms, demand side providers (“DSPs”) and proprietary platforms that we do not control; (viii) our ability to maintain high impression volumes; (ix) risks that our customers do not pay or choose to dispute their invoices; (x) our dependence on the overall demand for advertising; (xi) our ability to compete successfully with our current or future competitors in an intensely competitive market; (xii) our international expansion; (xiii) our ability to expand into new channels; (xiv) risks of material changes to revenue share agreements with certain DSPs; (xv) our ability to effectively manage our growth; (xvi) the impact that any acquisitions we have completed in the past and may consummate in the future, strategic investments, or alliances may have on our business, financial condition, and results of operations; (xvii) our ability to successfully execute our international plans; (xviii) the risks associated with the seasonality of our market; (xix) the difficulty in evaluating our future prospects given our short operating history; (xx) uncertainty in how the market for buying digital advertising verification solutions will evolve; (xxi) the risk that a perceived failure to comply with laws and industry self-regulation may damage our reputation; (xxii) interruption by man-made problems such as terrorism, computer viruses, or social disruptions; (xxiii) the risk of failures in the systems and infrastructure supporting our solutions and operations; (xxiv) our ability to avoid operational, technical, and performance issues with our platform; (xxv) risks associated with any unauthorized access to user, customer, or inventory and third-party provider data; (xxvi) our ability to provide the non-proprietary technology, software, products, and services that we use; (xxvii) the risk that we are sued by third parties for alleged infringement, misappropriation, or other violation of their proprietary rights; (xxviii) our ability to obtain, maintain, protect, or enforce intellectual property and proprietary rights that are important to our business; (xxix) our involvement in lawsuits to protect or enforce our intellectual property; (xxx) risks that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers; (xxxi) risks that our trademarks and trade names are not adequately protected; (xxxii) the impact of unforeseen changes to privacy and data protection laws and regulation on digital advertising; (xxxiii) our ability to maintain our corporate culture; (xxxiv) risks posed by earthquakes, fires, floods, and other natural catastrophic events; and (xxxv) other factors disclosed in our filings with the SEC. Given these factors, as well as other variables that may affect our operating results, you should not rely on forward-looking statements, assume that past financial performance will be a reliable indicator of future performance, or use historical trends to anticipate results or trends in future periods.

We derive many of our forward-looking statements from our operating budgets and forecasts, which are based on many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to update or revise any forward- looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Investor Contact:
Jonathan Schaffer
ir@integralads.com

Media Contact:
press@integralads.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ias-reports-first-quarter-2025-financial-results-302452711.html

SOURCE Integral Ad Science, Inc.